- 1. Name of the medicinal product
- 2. Qualitative and quantitative composition
- 3. Pharmaceutical form
- 4. Clinical particulars
- 4.1 Therapeutic indications
- 4.2 Posology and method of administration
- 4.3 Contraindications
- 4.4 Special warnings and precautions for use
- 4.5 Interaction with other medicinal products and other forms of interaction
- 4.6 Fertility, pregnancy and lactation
- 4.7 Effects on ability to drive and use machines
- 4.8 Undesirable effects
- 4.9 Overdose
- 5. Pharmacological properties
- 5.1 Pharmacodynamic properties
- 5.2 Pharmacokinetic properties
- 5.3 Preclinical safety data
- 6. Pharmaceutical particulars
- 6.1 List of excipients
- 6.2 Incompatibilities
- 6.3 Shelf life
- 6.4 Special precautions for storage
- 6.5 Nature and contents of container
- 6.6 Special precautions for disposal and other handling
- 7. Marketing authorisation holder
- 8. Marketing authorisation number(s)
- 9. Date of first authorisation/renewal of the authorisation
- 10. Date of revision of the text
The following materials are available for healthcare professionals:
INCIVO - Information Booklet for Health Care Professionals
This product has additional materials to provide guidance on appropriate management of associated dermatological reactions.
Managing Dermatological Reactions in Patients Treated with Incivo
This product has additional materials to provide guidance on appropriate management of associated dermatological reactions.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.
PosologyINCIVO, 1,125 mg (three 375 mg film-coated tablets) should be taken orally twice daily (b.i.d.) with food. Alternatively, 750 mg (two 375 mg tablets) can be taken orally every 8 hours (q8h) with food. The total daily dose is 6 tablets (2,250 mg). Taking INCIVO without food or without regard to the dosing interval may result in decreased plasma concentrations of telaprevir which could reduce the therapeutic effect of INCIVO.INCIVO should be administered in conjunction with ribavirin and either peginterferon alfa-2a or -2b. Please consult sections 4.4 and 5.1 regarding the selection of peginterferon alfa-2a or -2b. For specific dosage instructions for peginterferon alfa and ribavirin, the Summary of Product Characteristics for these medicinal products should be consulted.
Duration of treatment Treatment-naïve adults and prior treatment relapsersTreatment with INCIVO must be initiated in combination with peginterferon alfa and ribavirin and administered for 12 weeks (see figure 1).- Patients with undetectable hepatitis C virus ribonucleic acid (HCV RNA) (target not detected) at weeks 4 and 12 receive an additional 12 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 24 weeks.- Patients with detectable HCV RNA at either weeks 4 or 12 receive an additional 36 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 48 weeks.- For all patients with cirrhosis irrespective of undetectable HCV RNA (target not detected) at weeks 4 or 12, an additional 36 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 48 weeks is recommended (see section 5.1).
Figure 1: Duration of treatment for treatment-naïve patients and prior treatment relapsersHCV RNA levels should be monitored at weeks 4 and 12 to determine treatment duration. In Phase 3 studies, a sensitive real-time PCR assay with a limit of quantification of 25 IU/ml and a limit of detection of 10-15 IU/ml was used to determine whether HCV RNA levels were undetectable (target not detected) (see section 5.1). Detectable HCV RNA below the lower limit of assay quantification should not be used as a substitute for undetectable (target not detected), for making decisions on treatment duration, as this may lead to an insufficient duration of therapy and higher relapse rates. See table 1 for Guidelines for Discontinuation of INCIVO, Peginterferon Alfa, and Ribavirin Treatment.
Duration of treatment Previously treated adults with prior partial or prior null responseTreatment with INCIVO must be initiated in combination with peginterferon alfa and ribavirin and administered for 12 weeks, followed by peginterferon alfa and ribavirin therapy alone (without INCIVO) for a total treatment duration of 48 weeks (see figure 2).
Figure 2: Duration of treatment for previously treated patients with prior partial or prior null responseHCV RNA levels should be monitored at weeks 4 and 12. See table 1 for Guidelines for Discontinuation of INCIVO, Peginterferon Alfa, and Ribavirin Treatment.
All patientsSince it is highly unlikely that patients with inadequate viral responses will achieve a sustained virologic response (SVR), it is recommended that patients with HCV RNA > 1,000 IU/ml at week 4 or week 12 discontinue therapy (refer to table 1).
|Table 1: Guidelines for discontinuation of INCIVO, Peginterferon Alfa, and Ribavirin treatment|
|Medicinal products||HCV RNA > 1,000 IU/ml at week 4 of treatmenta||HCV RNA > 1,000 IU/ml at week 12 of treatmenta|
|INCIVO||Permanently discontinue||INCIVO treatment completed|
|Peginterferon alfa and Ribavirin||Permanently discontinue|
Renal impairmentThere are no clinical data on the use of INCIVO in HCV patients with moderate or severe renal impairment (CrCl ≤ 50 ml/min) (see section 4.4). In HCV-negative patients with severe renal impairment, no clinically relevant change in telaprevir exposure was observed (see section 5.2). Therefore, no dose adjustment is recommended for INCIVO in HCV patients with renal impairment.There are no clinical data on the use of INCIVO in patients on haemodialysis.Refer also to the Summary of Product Characteristics for ribavirin for patients with CrCl < 50 ml/min.
Hepatic impairmentINCIVO is not recommended in patients with moderate to severe hepatic impairment (Child-Pugh B or C, score ≥ 7) or decompensated liver disease (ascites, portal hypertensive bleeding, encephalopathy, and/or jaundice other than Gilbert's Syndrome, see section 4.4). Dose modification of INCIVO is not required when administered to hepatitis C patients with mild hepatic impairment (Child-Pugh A, score 5-6).Refer also to the Summary of Product Characteristics for peginterferon alfa and ribavirin which are contraindicated in Child-Pugh score ≥ 6.
HCV/Human immunodeficiency virus type (HIV)-1 co-infectionHCV/HIV-1 co-infected patients should be treated in the same way as HCV mono-infected patients. Drug interactions need to be carefully taken into account, see sections 4.4 and 4.5. Patients on an efavirenz-based regimen must receive INCIVO 1,125 mg every 8 hours. For outcomes obtained in HIV co-infected patients, see section 5.1.
ElderlyThere are limited clinical data on the use of INCIVO in HCV patients aged ≥ 65 years.
Paediatric populationThe safety and efficacy of INCIVO in children aged < 18 years have not yet been established.No data are available.
Method of administrationPatients should be instructed to swallow the tablets whole (e.g. patients should not chew, break or dissolve the tablet).
Severe rashSevere, potentially life-threatening and fatal skin reactions have been reported with INCIVO combination treatment. Toxic epidermal necrolysis (TEN) including fatal outcome has been observed in post-marketing experience (see section 4.8). Fatal cases have been reported in patients with progressive rash and systemic symptoms who continued to receive INCIVO combination treatment after a serious skin reaction was identified.In placebo-controlled Phase 2 and 3 trials, severe rash (primarily eczematous, pruritic and involving more than 50% body surface area) was reported in 4.8% of patients who received INCIVO combination treatment compared to 0.4% receiving peginterferon alfa and ribavirin. Available data suggest that peginterferon alfa, and perhaps also ribavirin, may contribute to the frequency and severity of rash associated with INCIVO combination treatment.5.8% of patients discontinued INCIVO alone due to rash events and 2.6% of patients discontinued INCIVO combination treatment for rash events compared to none of those receiving peginterferon alfa and ribavirin.In placebo-controlled Phase 2 and 3 trials, 0.4% of patients had suspected Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). In INCIVO clinical experience, less than 0.1% of patients had Stevens-Johnson Syndrome (SJS). All of these reactions resolved with treatment discontinuation.DRESS presents as a rash with eosinophilia associated with one or more of the following features: fever, lymphadenopathy, facial oedema, and internal organ involvement (hepatic, renal, pulmonary). It may appear at any time after start of treatment, although the majority of cases appeared between six and ten weeks after the start of treatment with INCIVO.Prescribers should ensure that patients are fully informed about the risk of severe rashes, and to consult with their prescriber immediately if they develop a new rash or worsening of an existing rash. All rashes should be monitored for progression and until the rash is resolved. The rash may take several weeks to resolve. Other medicinal products associated with severe cutaneous reactions should be used with caution during administration of INCIVO combination treatment to avoid potential confusion as to which medicinal product could be contributing to a severe cutaneous reaction. In the case of a serious skin reaction, discontinuation of other medicinal products known to be associated with serious skin reactions should be considered.For additional information on mild to moderate rash, see section 4.8.The recommendations for monitoring of cutaneous reactions, and for discontinuation of INCIVO, ribavirin and peginterferon alfa are summarised in the table below:
|Extent and features of Cutaneous Reactions||Recommendations for Monitoring of Cutaneous Reactions and Discontinuation of INCIVO, Ribavirin and Peginterferon alfa for Severe Rash|
|Mild rash: localised skin eruption and/or a skin eruption with a limited distribution (up to several isolated sites on the body)||Monitor for progression or systemic symptoms until the rash is resolved.|
|Moderate rash: Diffuse rash ≤ 50% of body surface area||Monitor for progression or systemic symptoms until the rash is resolved. Consider consultation with a specialist in dermatology. For moderate rash that progresses, permanent discontinuation of INCIVO should be considered. If the rash does not improve within 7 days following INCIVO discontinuation, ribavirin should be interrupted. Interruption of ribavirin may be required sooner if the rash worsens despite discontinuation of telaprevir. Peginterferon alfa may be continued unless interruption is medically indicated. For moderate rash that progresses to severe (≥ 50% body surface area), permanently discontinue INCIVO (see below).|
|Severe rash: Extent of rash > 50% of body surface area or associated with vesicles, bullae, ulcerations other than SJS||Permanently discontinue INCIVO immediately. Consultation with a specialist in dermatology is recommended. Monitor for progression or systemic symptoms until the rash is resolved. Peginterferon alfa and ribavirin may be continued. If improvement is not observed within 7 days of INCIVO discontinuation, sequential or simultaneous interruption or discontinuation of ribavirin and/or peginterferon alfa should be considered. If medically indicated, earlier interruption or discontinuation of peginterferon alfa and ribavirin may be needed.|
|Serious skin reactions including rash with systemic symptoms, progressive severe rash, suspicion or diagnosis of generalised bullous eruption, DRESS, SJS/TEN, acute generalized exanthematous pustulosis, erythema multiforme||Permanent and immediate discontinuation of INCIVO, peginterferon alfa, and ribavirin. Consult with a specialist in dermatology.|
AnaemiaIn placebo-controlled Phase 2 and 3 clinical trials, the overall incidence and severity of anaemia increased with INCIVO combination treatment compared to peginterferon alfa and ribavirin alone. Haemoglobin values of < 10 g/dl were observed in 34% of patients who received INCIVO combination treatment and in 14% of patients who received peginterferon alfa and ribavirin. Haemoglobin values of < 8.5 g/dl were observed in 8% of INCIVO combination treatment compared to 2% of patients receiving peginterferon alfa and ribavirin. A decrease in haemoglobin levels occurs during the first 4 weeks of treatment, with lowest values reached at the end of INCIVO dosing. Haemoglobin values gradually improve after completion of INCIVO dosing.Haemoglobin should be monitored at regular intervals prior to and during INCIVO combination treatment (see section 4.4, Laboratory tests).Ribavirin dose reduction is the preferred strategy for managing treatment-emergent anaemia. Refer to the Summary of Product Characteristics for ribavirin for information regarding dose reduction and/or discontinuation of ribavirin. If ribavirin is permanently discontinued for the management of anaemia, INCIVO must also be permanently discontinued. If INCIVO is discontinued for anaemia, patients may continue treatment with peginterferon alfa and ribavirin. Ribavirin may be restarted per the dosing modification guidelines for ribavirin. The dose of INCIVO must not be reduced, and INCIVO must not be restarted if discontinued.
Pregnancy and contraception requirementsBecause INCIVO must be used in combination with peginterferon alfa and ribavirin, the contraindications and warnings applicable to those medicinal products are applicable to combination therapy.Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin, therefore, extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients.Female patients of childbearing potential and their male partners as well as male patients and their female partners must use 2 effective contraceptive methods during INCIVO treatment and afterwards as recommended in the Summary of Product Characteristics for ribavirin, and as described below.Hormonal contraceptives may be continued but may not be reliable during INCIVO dosing and for up to two months following cessation of INCIVO (see section 4.5). During this time, female patients of childbearing potential should use two effective non-hormonal methods of contraception. Two months after completion of INCIVO treatment, hormonal contraceptives are again appropriate as one of the two required effective methods of birth control.For additional information, see sections 4.5 and 4.6.
CardiovascularResults of a study conducted in healthy volunteers demonstrated a modest effect of telaprevir at a dose of 1,875 mg every 8 hours on the QTcF interval with a placebo-adjusted maximum mean increase of 8.0 msec (90% CI: 5.1-10.9) (see section 5.1). Exposure at this dose was comparable to the exposure in HCV-infected patients receiving a dose of 750 mg INCIVO every 8 hours plus peginterferon alfa and ribavirin. The potential clinical significance of these findings is uncertain.INCIVO should be used with caution with Class Ic antiarrhythmics propafenone and flecainide, including appropriate clinical and ECG monitoring.Caution is recommended when prescribing INCIVO concurrently with medicinal products known to induce QT prolongation and which are CYP3A substrates such as erythromycin, clarithromycin, telithromycin, posaconazole, voriconazole, ketoconazole, tacrolimus, salmeterol (see section 4.5). INCIVO co-administration with domperidone should be avoided (see section 4.5). INCIVO may increase concentrations of the co-administered medicinal product and this may result in an increased risk of their associated cardiac adverse reactions. In the event that co-administration of such medicinal products with INCIVO is judged strictly necessary, clinical monitoring including ECG assessments is recommended. See also section 4.3 for medicinal products which are contraindicated with INCIVO.Use of INCIVO should be avoided in patients with congenital QT prolongation, or a family history of congenital QT prolongation or sudden death. In the event that treatment with INCIVO in such patients is judged strictly necessary, patients should be closely monitored, including ECG assessments.Use INCIVO with caution in patients with:- a history of acquired QT prolongation;- clinically relevant bradycardia (persistent heart rate < 50 bpm);- a history of heart failure with reduced left-ventricular ejection fraction;- a requirement for medicinal products known to prolong the QT interval but the metabolism of which is not mainly CYP3A4 dependent (e.g. methadone, see section 4.5).Such patients should be closely monitored, including ECG assessments.Electrolyte disturbances (e.g., hypokalaemia, hypomagnesaemia and hypocalcaemia) should be monitored and corrected, if necessary, prior to initiation and during INCIVO therapy.
Use in patients with advanced liver diseaseHypoalbuminaemia and low platelet counts have been identified as predictors of severe complications of liver disease as well as of interferon-based therapies (e.g., hepatic decompensation, serious bacterial infections). Furthermore, high rates of anaemia have been seen when using INCIVO with peginterferon and ribavirin in patients with these characteristics. INCIVO in combination with peginterferon and ribavirin is not recommended in patients with platelets < 90,000/mm3 and/or albumin < 3.3 g/dl. When INCIVO is used in patients with advanced liver disease very close monitoring and early management of adverse events is recommended.
Laboratory testsHCV RNA levels should be monitored at weeks 4 and 12 and as clinically indicated (see also guidelines for discontinuation of INCIVO, section 4.2).The following laboratory evaluations (complete blood count with white blood cell differential counts, electrolytes, serum creatinine, liver function tests, TSH, uric acid) must be conducted in all patients prior to initiating INCIVO combination treatment.These are recommended baseline values for initiation of INCIVO combination treatment:- Haemoglobin: ≥ 12 g/dl (females); ≥ 13 g/dl (males)- Platelet count ≥ 90,000/mm3- Absolute neutrophil counts ≥ 1,500/mm3- Adequately controlled thyroid function (TSH)- Calculated creatinine clearance ≥ 50 ml/min- Potassium ≥ 3.5 mmol/l- Albumin > 3.3 g/dlHaematology evaluations (including white cell differential count) are recommended at weeks 2, 4, 8 and 12 and as clinically appropriate.Chemistry evaluations (electrolytes, serum creatinine, uric acid, hepatic enzymes, bilirubin, TSH) are recommended as frequently as the haematology evaluations or as clinically indicated (see section 4.8).Refer to the Summary of Product Characteristics for peginterferon alfa and ribavirin, including pregnancy testing requirements (see section 4.6).
The use of INCIVO in combination with peginterferon alfa-2bThe Phase 3 studies were all conducted with peginterferon alfa-2a in combination with INCIVO and ribavirin. There is no data using INCIVO in combination with peginterferon alfa-2b in treatment-experienced patients and limited data in treatment-naïve patients. Naïve patients treated with either peginterferon alfa-2a/ribavirin (n = 80) or peginterferon alfa-2b/ribavirin (n = 81) in combination with INCIVO, in an open label study, had comparable SVR rates. However, patients treated with peginterferon alfa-2b experienced more frequent viral breakthrough, and were less likely to meet the criteria for shortened total treatment duration (see section 5.1).
GeneralINCIVO must not be administered as monotherapy and must only be prescribed in combination with both peginterferon alfa and ribavirin. The Summary of Product Characteristics for peginterferon alfa and ribavirin must therefore be consulted before starting therapy with INCIVO.There are no clinical data on re-treating patients who have failed an HCV NS3-4A protease inhibitor-based therapy (see section 5.1).
Insufficient virologic responseIn patients who have an inadequate viral response, treatment should be discontinued (see sections 4.2 and 4.4, Laboratory tests).
Use of INCIVO in treatment of other HCV genotypesThere are not sufficient clinical data to support the treatment of patients with HCV genotypes other than genotype 1. Therefore, the use of INCIVO in patients with non-genotype-1 HCV is not recommended.
Renal impairmentThe safety and efficacy have not been established in patients with moderate or severe renal impairment (CrCl < 50 ml/min) or in patients on haemodialysis. Refer to section 4.4, Laboratory tests. Refer also to the Summary of Product Characteristics for ribavirin for patients with CrCL < 50 ml/min (see also section 4.2 and 5.2).
Hepatic impairmentINCIVO has not been studied in patients with severe hepatic impairment (Child-Pugh C, score ≥ 10) or decompensated liver disease (ascites, portal hypertensive bleeding, encephalopathy, and/or jaundice other than Gilbert's Syndrome) and is not recommended in these populations.INCIVO has not been studied in HCV-infected patients with moderate hepatic impairment (Child-Pugh B, score 7-9). In HCV negative patients with moderate hepatic impairment, reduced exposure to telaprevir was observed. The appropriate dose of INCIVO in hepatitis C-infected patients with moderate hepatic impairment has not been determined. Therefore, INCIVO is not recommended in these patients (see sections 4.2 and 5.2).Refer to the Summary of Product Characteristics for peginterferon alfa and ribavirin which must be co-administered with INCIVO.
Organ transplant patientsNo clinical data are available regarding the treatment of pre-, peri-, or post-liver or other transplant patients with INCIVO in combination with peginterferon alfa and ribavirin (see also section 4.5, Immunosuppressants).
HCV/HIV co-infectionInteractions between telaprevir and HIV antiretroviral agents are frequent, and the recommendations in table 2, section 4.5, should be carefully followed.Among HIV regimens that can be used (not limited to those below) the following should be taken into account:Atazanavir/ritonavir: this combination is associated with a high frequency of hyperbilirubinaemia/icterus. In Study HPC3008 (see sections 4.8 and 5.1), transient grade 3 (2.5 to ≤5 X ULN) and grade 4 (>5 X ULN) bilirubin increases during INCIVO treatment were seen in 39% and in 22% of the 59 patients on atazanavir/ritonavir, respectively.Efavirenz: with this combination the telaprevir dose must be increased to 1125 mg three times per day (q8h).
HCV/HBV (hepatitis B virus) co-infectionThere are no data on the use of INCIVO in patients with HCV/HBV co-infection.
Paediatric populationINCIVO is not recommended for use in children and adolescents younger than 18 years of age because the safety and efficacy has not been established in this population.
Thyroid diseaseIncrease in thyroid stimulating hormone (TSH) may occur during INCIVO combination treatment, which may indicate worsening or recurrence of pre-existing or previous hypothyroidism, or new-onset hypothyroidism (see section 4.8). TSH levels should be determined before and during the course of INCIVO combination treatment and treated as clinically appropriate, including potential adjustment of thyroid replacement therapy in patients with pre-existing hypothyroidism (see section 4.4, Laboratory tests).
Interactions with medicinal productsTelaprevir is a strong inhibitor of the important drug metabolising enzyme CYP3A4. Increased systemic exposures are expected if telaprevir is combined with drugs highly metabolised by this enzyme. Refer to section 4.3 for a listing of medicinal products that are contraindicated for use with INCIVO due to potentially life-threatening adverse events or potential loss of therapeutic effect to INCIVO. Refer to section 4.5 for established and other potentially significant drug-drug interactions.
Important information about some of the ingredients of INCIVOThis medicinal product contains 2.3 mg sodium per tablet, which should be taken into consideration by patients on a controlled sodium diet.
Contraindications of concomitant use (see section 4.3)INCIVO must not be administered concurrently with active substances that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events such as cardiac arrhythmia (i.e., amiodarone, astemizole, bepridil, cisapride, pimozide, quinidine, terfenadine), or peripheral vasospasm or ischemia (i.e., dihydroergotamine, ergonovine, ergotamine, methylergonovine), or myopathy, including rhabdomyolysis (i.e., lovastatin, simvastatin, atorvastatin), or prolonged or increased sedation or respiratory depression (i.e., quetiapine, orally administered midazolam or triazolam), or hypotension or cardiac arrhythmia (i.e., alfuzosin and sildenafil for pulmonary arterial hypertension).INCIVO must not be administered concurrently with Class Ia or III antiarrhythmics, except for intravenous lidocaine.INCIVO should be used with caution with Class Ic antiarrhythmics propafenone and flecainide, including appropriate clinical and ECG monitoring (see section 4.4).
RifampicinRifampicin reduces the telaprevir plasma AUC by approximately 92%. Therefore, INCIVO must not be co-administered with rifampicin.
St John's wort (Hypericum perforatum)Plasma concentrations of telaprevir can be reduced by concomitant use of the herbal preparation St John's wort (Hypericum perforatum). Therefore, herbal preparations containing St John's wort must not be combined with INCIVO.
Carbamazepine, phenytoin and phenobarbitalCo-administration with inducers may lead to lower exposure of telaprevir with risk of lower efficacy. Potent CYP3A inducers, such as carbamazepine, phenytoin and phenobarbital, are contraindicated (see section 4.3).
Mild and moderate CYP3A inducersMild and moderate CYP3A inducers should be avoided, particularly in patients who are prior non-responders (partial or null responders for peginterferon alfa/ribavirin), unless specific dose recommendations are given (refer to table 2).
Other combinationsTable 2 provides dosing recommendations as a result of drug interactions with INCIVO. These recommendations are based on either drug interaction studies (indicated with *) or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy. Most drug-drug interaction studies have been performed with a telaprevir dose of 750 mg every 8 hours (q8h). Given that the 1,125 mg b.i.d. regimen results in the same daily dose with similar drug exposures of telaprevir, the relative drug interactions are expected to be similar.The direction of the arrow (↑ = increase, ↓ = decrease, ↔ = no change) for each pharmacokinetic parameter is based on the 90% confidence interval of the geometric mean ratio being within (↔), below (↓) or above (↑) the 80-125% range.
|Table 2: INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS|
|Medicinal products by therapeutic areas||Effect on concentration of INCIVO or concomitant medicinal product and possible mechanism||Clinical comment|
|alfentanil fentanyl||↑ alfentanil ↑ fentanyl||Careful monitoring of therapeutic and adverse effects (including respiratory depression) is recommended when telaprevir is co-administered with alfentanil or fentanyl, including oral, buccal, nasal and extended-release transdermal or transmucosal preparations of fentanyl, especially at initiation of treatment. Dosage adjustment of fentanyl or alfentanil may be necessary. The most marked effects are expected on oral, nasal and buccal/sublingual fentanyl formulations.|
|lidocaine (intravenous)||↑ lidocaine inhibition of CYP3A||Caution is warranted and clinical monitoring is recommended when intravenous lidocaine is administered for the treatment of acute ventricular arrhythmia.|
|digoxin*||↑ digoxin AUC 1.85 (1.70-2.00) Cmax 1.50 (1.36-1.65) effect on P-gp transport in the gut||The lowest dose of digoxin should be initially prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect.|
|clarithromycin erythromycin telithromycin troleandomycin||↑ telaprevir ↑ antibacterials inhibition of CYP3A||Caution is warranted and clinical monitoring is recommended when co-administered with INCIVO. QT interval prolongation and Torsade de Pointes have been reported with clarithromycin and erythromycin. QT interval prolongation has been reported with telithromycin (see section 4.4).|
|warfarin||↑ or ↓ warfarin modulation of metabolic enzymes||It is recommended that the international normalised ratio (INR) be monitored when warfarin is co-administered with telaprevir.|
|dabigatran||↑ dabigatran ↔ telaprevir effect on P-gp transport in the gut||Caution is warranted, laboratory and clinical monitoring is recommended.|
|carbamazepine*||↓ telaprevir AUC 0.68 (0.58-0.79) Cmax 0.79 (0.70-0.90) Cmin 0.53 (0.44-0.65) ↔ carbamazepine AUC 1.10 (0.99-1.23) Cmax 1.09 (0.98-1.21) Cmin 1.10 (0.97-1.24) induction of CYP3A by carbamazepine, and inhibition of CYP3A by telaprevir||Co-administration with carbamazepine is contraindicated.|
|phenytoin*||↓ telaprevir AUC 0.53 (0.47-0.60) Cmax 0.68 (0.60-0.77) Cmin 0.32 (0.25-0.42) ↑ phenytoin AUC 1.31 (1.15-1.49) Cmax 1.27 (1.09-1.47) Cmin 1.36 (1.21-1.53) induction of CYP3A by phenytoin, and inhibition of CYP3A by telaprevir||Co-administration with phenytoin is contraindicated.|
|phenobarbital||↓ telaprevir ↑ or ↓ phenobarbital induction of CYP3A by phenobarbital, and inhibition of CYP3A by telaprevir||Co-administration with phenobarbital is contraindicated.|
|escitalopram*||↔ telaprevir ↓ escitalopram AUC 0.65 (0.60-0.70) Cmax 0.70 (0.65-0.76) Cmin 0.58 (0.52-0.64) mechanism unknown||Clinical relevance unknown. Doses may need to be increased when combined with telaprevir.|
|trazodone||↑ trazodone inhibition of CYP3A||Concomitant use may lead to adverse events such as nausea, dizziness, hypotension and syncope. If trazodone is used with telaprevir, the combination should be used with caution and a lower dose of trazodone should be considered.|
|metformin||↑ metformin inhibition of MATE-1 and MATE2-K||Close monitoring of metformin efficacy and safety is recommended when starting or stopping INCIVO in patients receiving metformin. A dose adjustment of metformin may be necessary.|
|domperidone||↑ domperidone inhibition of CYP3A||Co-administration of domperidone with INCIVO should be avoided (see section 4.4).|
|ketoconazole* itraconazole posaconazole voriconazole||↑ ketoconazole (200 mg) AUC 2.25 (1.93-2.61) Cmax 1.75 (1.51-2.03) ↑ ketoconazole (400 mg) AUC 1.46 (1.35-1.58) Cmax 1.23 (1.14-1.33) ↑ telaprevir (with ketoconazole 400 mg) AUC 1.62 (1.45-1.81) Cmax 1.24 (1.10-1.41) ↑ itraconazole ↑ posaconazole ↑ or ↓ voriconazole Inhibition of CYP3A. Due to multiple enzymes involved with voriconazole metabolism, it is difficult to predict the interaction with telaprevir.||When co-administration is required, high doses of itraconazole (> 200 mg/day) or ketoconazole (> 200 mg/day) are not recommended. Caution is warranted and clinical monitoring is recommended for itraconazole, posaconazole, and voriconazole. QT interval prolongation and Torsade de Pointes have been reported with voriconazole and posaconazole. QT interval prolongation has been reported with ketoconazole (see section 4.4). Voriconazole should not be administered to patients receiving telaprevir unless an assessment of the benefit/risk ratio justifies its use.|
|colchicine||↑ colchicine inhibition of CYP3A||Patients with renal or hepatic impairment should not be given colchicine with INCIVO, due to the risk of colchicine toxicity. In patients with normal renal and hepatic function, an interruption of colchicine treatment is recommended, or only a limited colchicine treatment course at a reduced colchicine dose should be used.|
|rifabutin||↓ telaprevir ↑ rifabutin induction of CYP3A by rifabutin, inhibition of CYP3A by telaprevir||Telaprevir may be less effective due to decreased concentrations. The concomitant use of rifabutin and telaprevir is not recommended.|
|rifampicin*||↓ telaprevir AUC 0.08 (0.07-0.11) Cmax 0.14 (0.11-0.18) ↑ rifampicin induction of CYP3A by rifampicin, inhibition of CYP3A by telaprevir||Co-administration of rifampicin with telaprevir is contraindicated.|
|quetiapine||Due to CYP3A inhibition by telaprevir, concentrations of quetiapine are expected to increase.||Concomitant administration of INCIVO and quetiapine is contraindicated as it may increase quetiapine-related toxicity. Increased plasma concentrations of quetiapine may lead to coma.|
|alprazolam*||↑ alprazolam AUC 1.35 (1.23-1.49) Cmax 0.97 (0.92-1.03)||Clinical relevance unknown.|
|parenterally administered midazolam*
oral midazolam* |
|↑ midazolam (intravenous)
AUC 3.40 (3.04-3.79)
Cmax 1.02 (0.80-1.31)
↑ midazolam (p.o.) AUC 8.96 (7.75-10.35) Cmax 2.86 (2.52-3.25) ↑ triazolam inhibition of CYP3A
|Co-administration should be done in a setting which ensures clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation.
Dose reduction for parenterally administered midazolam should be considered, especially if more than a single dose of midazolam is administered. Co-administration of oral midazolam or triazolam with telaprevir is contraindicated.
|zolpidem (non-benzodiazepine sedative)*||↓ zolpidem AUC 0.53 (0.45-0.64) Cmax 0.58 (0.52-0.66) mechanism unknown||Clinical relevance unknown. Increased dose of zolpidem may be required to maintain efficacy.|
|CALCIUM CHANNEL BLOCKERS|
|amlodipine*||↑ amlodipine AUC 2.79 (2.58-3.01) Cmax 1.27 (1.21-1.33) inhibition of CYP3A||Caution should be used and dose reduction for amlodipine should be considered. Clinical monitoring is recommended.|
|diltiazem felodipine nicardipine nifedipine nisoldipine verapamil||↑ calcium channel blockers inhibition of CYP3A and/or effect on P-gp transport in the gut||Caution is warranted and clinical monitoring of patients is recommended.|
|maraviroc*||↑ maraviroc AUC12 9.49 (7.94-11.34) Cmax 7.81 (5.92-10.32) C12 10.17 (8.73-11.85) Telaprevir concentrations are not likely to be affected by maraviroc co-administration (based on historical data and the elimination pathway of telaprevir).||Maraviroc 150 mg twice daily when co-administered with telaprevir.|
|Systemic dexamethasone||↓ telaprevir induction of CYP3A||Concomitant use may result in loss of therapeutic effect of telaprevir. Therefore this combination should be used with caution or alternatives should be considered.|
|inhaled/nasal fluticasone budesonide||↑ fluticasone ↑ budesonide inhibition of CYP3A||Co-administration of fluticasone or budesonide and telaprevir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.|
|ENDOTHELIN RECEPTOR ANTAGONIST|
|bosentan||↑ bosentan ↓ telaprevir induction of CYP3A by bosentan, inhibition of CYP3A and organic anion transporter polypeptides (OATPs) by telaprevir||Caution is warranted and clinical monitoring is recommended.|
|HIV-ANTIVIRAL AGENTS: HIV-PROTEASE INHIBITORS (PIs)|
|atazanavir/ritonavir*||↓ telaprevir AUC 0.80 (0.76-0.85) Cmax 0.79 (0.74-0.84) Cmin 0.85 (0.75-0.98) ↑ atazanavir AUC 1.17 (0.97-1.43) Cmax 0.85 (0.73-0.98) Cmin 1.85 (1.40-2.44) inhibition of CYP3A by telaprevir||Hyperbilirubinaemia is frequent with this combination. Clinical and laboratory monitoring for hyperbilirubinaemia is recommended (see section 4.4 and 4.8).|
|darunavir/ritonavir*||↓ telaprevir AUC 0.65 (0.61-0.69) Cmax 0.64 (0.61-0.67) Cmin 0.68 (0.63-0.74) ↓ darunavir AUC 0.60 (0.57-0.63) Cmax 0.60 (0.56-0.64) Cmin 0.58 (0.52-0.63) mechanism unknown||It is not recommended to co-administer darunavir/ritonavir and telaprevir (see section 4.4).|
|fosamprenavir/ritonavir*||↓ telaprevir AUC 0.68 (0.63-0.72) Cmax 0.67 (0.63-0.71) Cmin 0.70 (0.64-0.77) ↓ amprenavir AUC 0.53 (0.49-0.58) Cmax 0.65 (0.59-0.70) Cmin 0.44 (0.40-0.50) mechanism unknown||It is not recommended to co-administer fosamprenavir/ritonavir and telaprevir (see section 4.4).|
|lopinavir/ritonavir*||↓ telaprevir AUC 0.46 (0.41-0.52) Cmax 0.47 (0.41-0.52) Cmin 0.48 (0.40-0.56) ↔ lopinavir AUC 1.06 (0.96-1.17) Cmax 0.96 (0.87-1.05) Cmin 1.14 (0.96-1.36) mechanism unknown||It is not recommended to co-administer lopinavir/ritonavir and telaprevir (see section 4.4).|
|HIV-ANTIVIRAL AGENTS: REVERSE TRANSCRIPTASE INHIBITORS|
|efavirenz*||↓ telaprevir 1,125 mg every 8 hours (relative to 750 mg every 8 hours) AUC 0.82 (0.73-0.92) Cmax 0.86 (0.76-0.97) Cmin 0.75 (0.66-0.86) ↓ efavirenz (+ TVR 1,125 mg every 8 hours) AUC 0.82 (0.74-0.90) Cmax 0.76 (0.68-0.85) Cmin 0.90 (0.81-1.01) induction of CYP3A by efavirenz.||If co-administered, telaprevir 1,125 mg q8h should be used (see section 4.4).|
|tenofovir disoproxil fumarate*||↔ telaprevir AUC 1.00 (0.94-1.07) Cmax 1.01 (0.96-1.05) Cmin 1.03 (0.93-1.14) ↑ tenofovir AUC 1.30 (1.22-1.39) Cmax 1.30 (1.16-1.45) Cmin 1.41 (1.29-1.54) effect on P-gp transport in the gut||Increased clinical and laboratory monitoring are warranted (see section 4.4).|
|abacavir zidovudine||Not studied.||An effect of telaprevir on UDP-glucuronyltransferases cannot be ruled out and may affect the plasma concentrations of abacavir or zidovudine.|
|etravirine*||↓ telaprevir 750 mg q8h AUC 0.84 (0.71-0.98) Cmax 0.90 (0.79-1.02) Cmin 0.75 (0.61-0.92) ↔ etravirine (+ TVR 750 mg q8h) AUC 0.94 (0.85-1.04) Cmax 0.93 (0.84-1.03) Cmin 0.97 (0.86-1.10)||If co-administered, no dose adjustment is required.|
|rilpivirine*||↓ telaprevir 750 mg q8h AUC 0.95 (0.76-1.18) Cmax 0.97 (0.79-1.21) Cmin 0.89 (0.67-1.18) ↑ rilpivirine (+ TVR 750 mg q8h) AUC 1.78 (1.44-2.20) Cmax 1.49 (1.20-1.84) Cmin 1.93 (1.55-2.41)||If co-administered, no dose adjustment is required.|
|raltegravir*||↔ telaprevir AUC 1.07 (1.00-1.15) Cmax 1.07 (0.98-1.16) Cmin 1.14 (1.04-1.26) ↑ raltegravir AUC 1.31 (1.03-1.67) Cmax 1.26 (0.97-1.62) Cmin 1.78 (1.26-2.53)||If co-administered, no dose adjustment is required.|
|HMG-CoA REDUCTASE INHIBITORS|
|atorvastatin*||↑ atorvastatin AUC 7.88 (6.82-9.07) Cmax 10.6 (8.74-12.85) inhibition of CYP3A and OATPs by telaprevir||Co-administration of atorvastatin and telaprevir is contraindicated (see section 4.3).|
|fluvastatin pitavastatin pravastatin rosuvastatin||↑ statin inhibition of CYP3A and OATPs by telaprevir||Caution is warranted and clinical monitoring is recommended. Refer to section 4.3 for HMG-CoA reductase inhibitors that are contraindicated with INCIVO.|
|ethinylestradiol* norethindrone*||↓ ethinylestradiol AUC 0.72 (0.69-0.75) Cmax 0.74 (0.68-0.80) Cmin 0.67 (0.63-0.71) ↔ norethindrone AUC 0.89 (0.86-0.93) Cmax 0.85 (0.81-0.89) Cmin 0.94 (0.87-1.00) mechanism unknown||Additional methods of non-hormonal contraception should be used when hormonal contraceptives are co-administered with telaprevir. Patients using oestrogens as hormone replacement therapy should be clinically monitored for signs of oestrogen deficiency. Refer to sections 4.4 and 4.6.|
|cyclosporine* tacrolimus* sirolimus||↑ cyclosporine AUC 4.64 (3.90-5.51) Cmax 1.32 (1.08-1.60) ↑ tacrolimus AUC 70.3 (52.9-93.4)** Cmax 9.35 (6.73-13.0)** ↑ sirolimus ↑ telaprevir **calculated based on data obtained with a reduced dose inhibition of CYP3A, inhibition of transport proteins||Significant immunosuppressant dose reductions and prolongation of the dosing intervals will be required. Close monitoring of immunosuppressant blood levels, renal function and immunosuppressant related side effects are recommended when co-administered with telaprevir. Tacrolimus may prolong the QT interval (see section 4.4).|
|INHALED BETA AGONIST|
|salmeterol||↑ salmeterol inhibition of CYP3A||Concurrent administration of salmeterol and telaprevir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia (see section 4.4).|
|repaglinide||↑ repaglinide inhibition of OATPs by telaprevir||Caution is warranted and clinical monitoring is recommended.|
|methadone*||↓ R-methadone AUC 0.71 (0.66-0.76) Cmax 0.71 (0.66-0.76) Cmin 0.69 (0.64-0.75) No effect on unbound R-methadone concentrations. Displacement of methadone from plasma proteins.||No adjustment of methadone dose is required when initiating co-administration of telaprevir. However, clinical monitoring is recommended as the dose of methadone during maintenance therapy may need to be adjusted in some patients. QT interval prolongation and Torsade de Pointes have been reported with methadone (see section 4.4). ECG should be monitored at baseline and regularly during telaprevir treatment.|
|buprenorphine*||↔ buprenorphine AUC 0.96 (0.84-1.10) Cmax 0.80 (0.69-0.93) Cmin 1.06 (0.87-1.30)||No adjustment of the buprenorphine dose is required when co-administered with telaprevir.|
|sildenafil tadalafil vardenafil||↑ PDE-5 inhibitors inhibition of CYP3A||It is not recommended to co-administer sildenafil or vardenafil and telaprevir. Tadalafil for treatment of erectile dysfunction can be used with caution at a single dose not exceeding 10 mg dose in 72 hours and with increased monitoring for tadalafil associated adverse events. Co-administration of sildenafil or tadalafil and telaprevir in the treatment of pulmonary arterial hypertension is contraindicated (see section 4.3).|
|PROTON PUMP INHIBITORS|
|esomeprazole*||↔ telaprevir AUC 0.98 (0.91-1.05) Cmax 0.95 (0.86-1.06)||Proton pump inhibitors can be used without dose modification.|
PregnancyThere are no data from the use of INCIVO in pregnant women. Animal studies are insufficient with respect to human reproductive toxicity (see section 5.3). INCIVO is not recommended during pregnancy and in women of childbearing potential not using contraception.
Contraception in males and femalesBecause INCIVO must be used in combination with peginterferon alfa and ribavirin, the contraindications and warnings applicable to those medicinal products are applicable to combination therapy.Due to the combined treatment with peginterferon alfa and ribavirin, female patients of childbearing potential and their male partners as well as male patients and their female partners must use 2 effective contraceptive methods during INCIVO treatment. Following completion of INCIVO therapy contraceptive recommendations should be followed as in the Summary of Product Characteristics for ribavirin, and as described below.Hormonal contraceptives may be continued but may not be reliable during INCIVO dosing and for up to two months following cessation of INCIVO (see section 4.5). During this time, female patients of childbearing potential should use two effective non-hormonal methods of contraception. Two months after completion of INCIVO treatment, hormonal contraceptives are again appropriate as one of the two required effective methods of birth control.Refer to the Summary of Product Characteristics for ribavirin and peginterferon alpha for additional information.
Breast-feedingTelaprevir and its major metabolite are excreted in rat milk (see section 5.3). It is not known whether telaprevir is excreted in human breast milk. Because of the potential for adverse reactions in breastfed infants, due to the combined treatment of INCIVO with peginterferon alfa and ribavirin, breast-feeding must be discontinued prior to initiation of therapy. See also the Summary of Product Characteristics for ribavirin.
FertilityINCIVO had no effects on fertility or fecundity when evaluated in rats.
Summary of the safety profileThe overall safety profile of INCIVO is based on Phase 2 and 3 clinical trial data (both controlled and uncontrolled) containing 3,441 patients who received INCIVO combination treatment and on spontaneous postmarketing reports.INCIVO must be administered with peginterferon alfa and ribavirin. Refer to their respective Summary of Product Characteristics for their associated adverse reactions.The incidence of adverse drug reactions (ADRs) of at least moderate intensity (≥ Grade 2) was higher in the INCIVO group than in the placebo group.During the INCIVO/placebo treatment phase, the most frequently reported ADRs of at least Grade 2 in severity in the INCIVO group (incidence ≥ 5.0%) were anaemia, rash, pruritus, nausea, and diarrhoea.During the INCIVO/placebo treatment phase, the most frequently reported ADRs of at least Grade 3 in the INCIVO group (incidence ≥ 1.0%) were anaemia, rash, thrombocytopenia, lymphopenia, pruritus, and nausea.
Tabulated summary of adverse reactionsADRs to INCIVO are presented in table 3.ADRs are listed by system organ class (SOC) and frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and rare (≥ 1/10,000 to < 1/1,000). Within each frequency grouping, ADRs are presented in order of decreasing seriousness.
|Table 3: Adverse drug reactions to INCIVO (taken in combination with peginterferon alfa and ribavirin) in HCV-infected patients in clinical trialsa and post-marketing|
|System Organ Class (SOC)||Frequency category||Adverse Drug ReactionsINCIVO, peginterferon alfa, and ribavirin combination therapy|
|Infections and infestations||common||oral candidiasis|
|Blood and lymphatic system disorders||very common||anaemia|
|Metabolism and nutrition disorders||common||hyperuricaemiab, hypokalaemiab|
|Nervous system disorders||common||dysgeusia, syncope|
|Gastrointestinal disorders||very common||nausea, diarrhoea, vomiting, haemorrhoids, proctalgia|
|common||anal pruritus, rectal haemorrhage, anal fissure|
|Skin and subcutaneous tissue disorders||very common||pruritus, rash|
|common||eczema, swelling face, exfoliative rash|
|uncommon||drug rash with eosinophilia and systemic symptoms (DRESS), urticaria|
|rare||SJS, TEN, erythema multiforme|
|Renal and urinary disorders||uncommon||blood creatinine increasedb, pre-renal azotemia with or without acute renal failure|
|General disorders and administration site conditions||common||oedema peripheral, product taste abnormal|
Laboratory abnormalitiesSelected laboratory abnormalities of at least moderate intensity (≥ Grade 2) that represent a worsening from baseline and are considered ADRs observed in HCV-infected patients treated with INCIVO combination treatment from the pooled data from the placebo-controlled Phase 2 and Phase 3 trials are presented in the table below:
|Table 4: Selected laboratory abnormalities (DAIDSa Grade ≥ 2) that represent a worsening from baseline and are considered adverse drug reactions in HCV-infected patients treated with INCIVO combination treatment from the pooled data from the placebo-controlled Phase 2 and Phase 3 trials|
|Grade 2||Grade 3||Grade 4|
|uric acid||17.9% (10.1-12.0 mg/dl)||4.6% (12.1-15.0 mg/dl)||1.1% (> 15.0 mg/dl)|
|bilirubin||13.6% (1.6-2.5 x ULN)||3.6% (2.6-5.0 x ULN)||0.3% (> 5.0 x ULN)|
|total cholesterol||15.4% (6.207.77 mmol/l 240 - 300 mg/dl)||2.0% (> 7.77 mmol/l > 300 mg/dl)||NA|
|low-density lipoprotein||6.9% (4.134.90 mmol/l 160190 mg/dl)||2.5% (≥ 4.91 mmol/l ≥ 191 mg/dl)||NA|
|creatinine||0.9% (1.41.8 x ULN)||0.2% (1.9-3.4 x ULN)||0% (> 3.4 x ULN)|
|haemoglobin||27.0% (9.0-9.9 g/dl or any decrease 3.5-4.4 g/dl)||51.1% (7.0-8.9 g/dl or any decrease ≥ 4.5 g/dl)||1.1% (< 7.0 g/dl)|
|platelet count||24.4% (50,00099,999/mm3)||2.8% (25,00049,999/mm3)||0.2% (< 25,000/mm3)|
|absolute lymphocyte count||13.1% (500-599/mm3)||11.8% (350-499/mm3)||4.8% (< 350/mm3)|
|potassium||1.6% (2.52.9 mEq/l)||0% (2.0-2.4 mEq/l)||0% (< 2.0 mEq/l)|
Description of selected adverse reactions
RashSevere, potentially life-threatening and fatal skin reactions have been reported with INCIVO combination treatment, including DRESS, SJS, and TEN (see section 4.4). In placebo-controlled Phase 2 and 3 trials, the overall incidence and severity of rash increased when INCIVO was co-administered with peginterferon alfa and ribavirin. During INCIVO treatment, rash events (all grades) were reported in 55% of patients who received INCIVO combination treatment and in 33% of patients who received peginterferon alfa and ribavirin.More than 90% of rashes were of mild or moderate severity. The rash reported during INCIVO combination treatment was assessed as a typically pruritic, eczematous rash, and involved less than 30% of body surface area. Half the rashes started during the first 4 weeks, but rash can occur at any time during INCIVO combination treatment. Discontinuation of INCIVO combination treatment is not required for mild and moderate rash.See section 4.4 for recommendations for monitoring of rash and discontinuation of INCIVO, ribavirin, and peginterferon alfa. Patients experiencing mild to moderate rash should be monitored for signs of progression; however, progression was infrequent (less than 10%). In clinical trials, the majority of patients were administered antihistamines and topical corticosteroids. Improvement of rash occurs after INCIVO dosing completion or discontinuation; however, rashes may take several weeks to resolve.
AnaemiaIn placebo-controlled Phase 2 and 3 trials, anaemia (all grades) was reported in 32.1% of patients who received INCIVO combination treatment and in 14.8% of patients who received peginterferon alfa and ribavirin. Ribavirin dose reductions were used for management of anaemia. 21.6% of patients receiving INCIVO combination treatment required ribavirin dose reduction for anaemia compared to 9.4% of patients receiving peginterferon alfa and ribavirin alone. Erythropoisis-stimulating agents (ESAs) were generally not permitted and used in only 1% of patients in the Phase 2 and 3 clinical trials. In the placebo-controlled Phase 2 and 3 trials, transfusions were reported during the INCIVO/placebo treatment phase in 2.5% of patients receiving INCIVO combination treatment and 0.7% in patients receiving peginterferon alfa and ribavirin alone. Transfusion rates over the whole study period were 4.6% and 1.6%, respectively. In placebo-controlled Phase 2 and 3 trials, 1.9% of patients discontinued INCIVO alone due to anaemia, and 0.9% of patients discontinued INCIVO combination treatment due to anaemia compared to 0.5% receiving peginterferon alfa and ribavirin (see section 4.4).
Anorectal signs and symptomsIn clinical trials, the majority of these events (e.g., haemorrhoids, anorectal discomfort, anal pruritus, and rectal burning) were mild to moderate, very few led to treatment discontinuation and resolved after completion of INCIVO dosing.
Patients Co-infected with HIV-1The overall safety profile of INCIVO in HCV/HIV-1 co-infected patients (either not on antiretroviral therapy or on antiretroviral therapy) was similar to the safety profile in mono-infected HCV patients, except for patients receiving atazanavir/ritonavir who frequently experienced a transient increase in indirect bilirubin levels (including grades 3 to 4) through week 2, returning to near baseline by week 12 (see section 4.4).
Paediatric populationThe safety and efficacy of INCIVO in children aged < 18 years have not yet been established.No data are available.
Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
United KingdomYellow Card SchemeWebsite: www.yellowcard.mhra.gov.uk
IrelandHPRA PharmacovigilanceEarlsfort Terrace IRL - Dublin 2Tel: +353 1 6764971Fax: +353 1 6762517Website: www.hpra.ieE-mail: email@example.com
Mechanism of actionTelaprevir is an inhibitor of the HCV NS34A serine protease, which is essential for viral replication.In vitro studies
Activity of telaprevir against HCVIn an HCV subtype 1b replicon assay, the telaprevir IC50 value against wild-type HCV was 0.354 µM similar to a subtype 1a infectious virus assay IC50 of 0.28 µM.
ResistanceHCV variants associated with on-treatment virologic failure or relapse were evaluated by site-directed mutagenesis in the replicon assay. Variants V36A/M, T54A/S, R155K/T, and A156S conferred lower levels of in vitro resistance to telaprevir (3- to 25-fold increase in telaprevir IC50), and the A156V/T and V36M+R155K variants conferred higher levels of in vitro resistance to telaprevir (> 25-fold increase in telaprevir IC50). Replicon variants generated from patient-derived sequences showed similar results.The in vitro replication capacity of telaprevir-resistant variants was lower than that of wild-type virus.
Cross-resistanceTelaprevir-resistant variants were tested for cross-resistance against representative protease inhibitors in the HCV replicon system. Replicons with single substitutions at position 155 or 156 and double variants with substitutions at residues 36 and 155 showed cross-resistance to all protease inhibitors tested with a wide range of sensitivities. All telaprevir-resistant variants studied remained fully sensitive to interferon-alfa, ribavirin, and representative HCV nucleoside and non-nucleoside polymerase inhibitors in the replicon system. There are no clinical data on re-treating patients who have failed an HCV NS3-4A protease inhibitor-based therapy, such as telaprevir, nor are there data on repeated courses of telaprevir treatment.
Clinical virology studiesIn Phase 2 and 3 clinical trials of telaprevir, treatment-naïve and prior treatment-failure patients with predominant telaprevir-resistant variants at baseline (pre-treatment) were rare (V36M, T54A and R155K < 1% and T54S 2.7%). Predominant baseline resistance to telaprevir does not preclude successful treatment with telaprevir, peginterferon alfa, and ribavirin. The impact of predominant telaprevir-resistant variants at baseline is likely greatest in patients with a poor interferon response, such as prior null responders.A total of 215 of 1,169 patients treated with a T12/PR regimen in a Phase 3 clinical trial had on-treatment virologic failure (n = 125) or relapse (n = 90). Based on population sequencing analyses of HCV in these 215 patients, the emergence of telaprevir-resistant HCV variants was detected in 105 (84%) virologic failures and in 55 (61%) relapsers, and wild-type virus was detected in 15 (12%) virologic failures and in 24 (27%) relapsers. HCV sequencing data were not available for 16 (7%) patients. Sequence analyses of the telaprevir-resistant variants identified substitutions at 4 positions in the NS3-4A protease region, consistent with the mechanism of action for telaprevir (V36A/M, T54A/S, R155K/T, and A156S/T/V). In the C211 Phase 3 clinical trial, there was no difference in the type of emerging variants between patients receiving telaprevir 1,125 mg twice daily (b.i.d.) and patients receiving telaprevir 750 mg every 8 hours (q8h). Similar proportions of patients in both treatment groups had telaprevir-resistant variants at the time of failure. On-treatment virologic failure during telaprevir treatment was predominantly associated with higher-level resistant variants, and relapse was predominantly associated with lower-level resistant variants or wild-type virus.Patients with HCV genotype 1a predominately had V36M and R155K single and combination variants, while patients with HCV genotype 1b predominately had V36A, T54A/S, and A156S/T/V variants. This difference is likely due to the higher genetic barrier for the V36M and R155K substitutions for genotype 1b than genotype 1a. Among patients treated with telaprevir, on-treatment virologic failure was more frequent in patients with genotype 1a than with genotype 1b and more frequent in prior null responders than in other populations (treatment-naïve, prior relapsers, prior partial responders; see section 5.1, Clinical Experience, Efficacy in Previously Treated Adults).The resistance profile observed in Study HPC3008 in HCV/HIV-1 co-infected patients was similar to the resistance profile in mono-infected HCV patients.Follow-up analysis of INCIVO-treated patients who did not achieve an SVR showed that the population of wild-type virus increased and the population of telaprevir-resistant variants became undetectable over time after the end of telaprevir treatment. Of a combined 255 treatment-naïve and previously treated patients from Phase 3 studies 108, 111, and C216 in whom telaprevir-resistant variants had emerged during treatment, 152 (60%) patients no longer had resistant variants detected by population sequencing (median follow-up of 10 months). Of the 393 resistant variants detected in the 255 patients, 68% of NS3-36, 84% of NS3-54, 59% of NS3-155, 86% of NS3-156, and 52% of NS3-36M+NS3-155K variants were no longer detected.In a follow-up study of 98 treatment-naïve and prior treatment-failure patients who were treated with a INCIVO regimen in a Phase 2 or Phase 3study and did not achieve SVR, telaprevir-resistant variants were no longer detected in 85% (83/98) of patients (median follow-up of 27.5 months). Clonal sequencing analysis of a subset of patients who had wild-type HCV by population sequencing (n=20), comparing the frequency of resistant variants before the start of telaprevir treatment and at follow-up, showed that the HCV variant population in all patients had returned to pre-treatment levels. The median time for telaprevir-resistant variants to become undetectable by population sequencing was longer for variants NS3-36 (6 months), NS3-155 (9 months) and NS3-36M+NS3-155K (12 months) predominantly observed in patients with genotype 1a than for variants NS3-54 (2 months) and NS3-156 (3 months) predominantly observed in patients with genotype 1b.
Clinical efficacy and safetyThe efficacy and safety of INCIVO in patients with genotype 1 chronic hepatitis C were evaluated in four Phase 3 studies: 3 in treatment-naïve patients and 1 in previously treated patients (relapsers, partial responders, and null responders). Patients in these studies, 108, 111 and C216, had compensated liver disease, detectable HCV RNA, and liver histopathology consistent with chronic hepatitis C. Unless otherwise indicated, INCIVO was administered at a dosage of 750 mg every 8 hours (q8h); the peginterferon alfa-2a dose was 180 µg/week, and the ribavirin dose was 1,000 mg/day (patients weighing < 75 kg) or 1,200 mg/day (patients weighing ≥ 75 kg). Plasma HCV RNA values were measured using the COBAS® TaqMan® HCV test (version 2.0), for use with the High Pure System. The assay had a lower limit of quantification of 25 IU/ml.In the description of Phase 3 study outcomes for Studies 108, 111, and C216, SVR, considered virologic cure, was defined based on the HCV RNA assessment in the study week 72 visit window, using the last measurement in the window. In the case of missing data within the week 72 window, the last HCV RNA data point from week 12 of follow-up onwards was used. In addition, the limit of quantification of 25 IU/ml was used to determine SVR.In the description of the Phase 3 study outcomes for Study C211 and HPC3008, SVR12, considered virologic cure, was defined based on HCV RNA below the limit of quantification (25 IU/ml) using the last measurement in the visit window 12 weeks after the planned end of treatment.
Efficacy in treatment-naïve adults
Study C211Study C211 was a randomised, open-label, Phase 3 study conducted in treatment-naïve patients who were randomised to one of two treatment groups: INCIVO 750 mg every 8 hours [T12(q8h)/PR] or INCIVO 1,125 mg twice daily [T12(b.i.d.)/PR] in combination with peginterferon alfa-2a and ribavirin. The primary objective was to demonstrate the noninferiority of T12(b.i.d.)/PR over T12(q8h)/PR. All patients received 12 weeks of treatment with INCIVO in combination with peginterferon alfa-2a and ribavirin. At week 12, INCIVO dosing ended and patients continued on peginterferon alfa-2a and ribavirin treatment. The total treatment duration was determined based on the patients' individual on-treatment viral response. If a patient achieved undetectable HCV RNA (target not detected) at week 4, the total treatment duration was 24 weeks. Otherwise, the total treatment duration was 48 weeks.The 740 enrolled patients had a median age of 51 years (range: 18 to 70); 60% of the patients were male; 21% had a body mass index ≥ 30 kg/m2; 5% were Black; 2% were Asian; 85% had baseline HCV RNA levels ≥ 800,000 IU/ml; 15% had bridging fibrosis; 14% had cirrhosis; 57% had HCV genotype 1a; and 43% had HCV genotype 1b.The SVR12 rate for the T12(b.i.d.)/PR group was 74% (274/369) compared to 73% (270/371) in the T12(q8h)/PR group with 95% confidence interval of the difference: -4.9%, 12.0%. The lower limit of the 95% CI (-4.9%) was greater than the pre-determined noninferiority margin of -11% and therefore the non inferiority of T12(b.i.d.)/PR over T12(q8h)/PR was demonstrated. Table 5 shows the response rates for the T12(b.i.d.)/PR group and the T12(q8h)/PR group.
|Table 5: Response rates: Study C211|
|Treatment outcome||T12(b.i.d.)/PRN = 369% (n/N)||T12(q8h)/PRN = 371% (n/N)|
|SVR12||74% (274/369)||73% (270/371)|
|Undetectable HCV RNA (target not detected) at week 4a||69% (256/369)||67% (250/371)|
|Undetectable HCV RNA (target not detected) at weeks 4 and 12||66% (244/369)||63% (234/371)|
|SVR in patients with undetectable HCV RNA (target not detected) at weeks 4 and 12||89% (218/244)||89% (209/234)|
|SVR in patients who did not have undetectable HCV RNA (target not detected) at weeks 4 and 12||45% (56/125)||45% (61/137)|
|Patients without SVR||26% (95/369)||27% (101/371)|
|On-treatment virologic failureb||10% (38/369)||10% (36/371)|
|Relapsec||8% (23/300)||6% (19/293)|
|Otherd||9% (34/369)||12% (46/371)|
|Table 6: SVR rates for patient subgroups: Study C211|
|Subgroup||T12(b.i.d.)/PRN = 369% (n/N)||T12(q8h)/PRN = 371% (n/N)|
|CC||92% (97/105)||87% (92/106)|
|CT||67% (139/206)||68% (141/208)|
|TT||66% (38/58)||65% (37/57)|
|Baseline liver fibrosis|
|No fibrosis or minimal fibrosis||80% (138/172)||79% (140/177)|
|Portal fibrosis||79% (75/95)||80% (68/85)|
|Bridging fibrosis||67% (32/48)||64% (38/59)|
|Cirrhosis||54% (29/54)||49% (24/49)|
Study 108 (ADVANCE)Study 108 was a randomised, double-blind, parallel-group, placebo-controlled, Phase 3 study conducted in treatment-naïve patients. INCIVO was given for the first 8 weeks of treatment (T8/PR regimen) or the first 12 weeks of treatment (T12/PR regimen) in combination with peginterferon alfa-2a and ribavirin for either 24 or 48 weeks. Patients who had undetectable HCV RNA (target not detected) at weeks 4 and 12 received 24 weeks of peginterferon alfa-2a and ribavirin treatment, and patients who did not have undetectable HCV RNA (target not detected) at week 4 and week 12 received 48 weeks of peginterferon alfa-2a and ribavirin treatment. The control regimen (Pbo/PR) had a fixed treatment duration of 48 weeks, with telaprevir-matching placebo for the first 12 weeks and peginterferon alfa-2a and ribavirin for 48 weeks.The 1,088 enrolled patients had a median age of 49 years (range: 18 to 69); 58% of the patients were male; 23% had a body mass index ≥ 30 kg/m2; 9% were Black; 11% were Hispanic or Latino; 77% had baseline HCV RNA levels ≥ 800,000 IU/ml; 15% had bridging fibrosis; 6% had cirrhosis; 59% had HCV genotype 1a; and 40% had HCV genotype 1b.The SVR rate for the T8/PR group was 72% (261/364) (P < 0.0001 compared to Pbo/PR48 group). Table 7 shows the response rates for the recommended T12/PR and the Pbo/PR48 groups.
|Table 7: Response rates: Study 108|
|Treatment outcome||T12/PRN = 363n/N (%)||Pbo/PR48N = 361n/N (%)|
|SVRa||79% (285/363) (74%, 83%)b||46% (166/361) (41%, 51%)b|
|Undetectable HCV RNA (target not detected) at weeks 4 and 12 ( eRVR)||58% (212/363)||8% (29/361)|
|SVR in eRVR patients||92% (195/212)||93% (27/29)|
|No eRVR||42% (151/363)||92% (332/361)|
|SVR in no eRVR patients||60% (90/151)||42% (139/332)|
|HCV RNA < 25 IU/ml at End of Treatment||82% (299/363)||62% (225/361)|
|Relapse||4% (13/299)||26% (58/225)|
|Table 8: SVR rates for patient subgroups: Study 108|
|Men||78% (166/214)||46% (97/211)|
|45 to ≤ 65 years of age||73% (157/214)||39% (85/216)|
|Black||62% (16/26)||29% (8/28)|
|Hispanic Latino||77% (27/35)||39% (15/38)|
|BMI ≥ 30 kg/m2||73% (56/77)||44% (38/87)|
|Baseline HCV RNA ≥ 800,000 IU/ml||77% (215/281)||39% (109/279)|
|HCV genotype 1a||75% (162/217)||43% (90/210)|
|HCV genotype 1b||84% (119/142)||51% (76/149)|
|Baseline liver fibrosis|
|No fibrosis, minimal fibrosis, or portal fibrosis||82% (237/290)||49% (140/288)|
|Bridging fibrosis||63% (33/52)||35% (18/52)|
|Cirrhosis||71% (15/21)||38% (8/21)|
Study 111 (ILLUMINATE)Study 111 was a Phase 3, randomised, open label study conducted in treatment-naïve patients. The study was designed to compare SVR rates in patients with undetectable HCV RNA ( target not detected) at weeks 4 and 12 who were treated with INCIVO for 12 weeks in combination with peginterferon alfa-2a and ribavirin for either 24 weeks (T12/PR24 regimen) or 48 weeks (T12/PR48 regimen). Patients with undetectable HCV RNA ( target not detected) at weeks 4 and 12 were randomised at week 20 to receive either 24 weeks or 48 weeks of peginterferon alfa-2a and ribavirin treatment. The primary assessment was an evaluation of non-inferiority, using a margin of -10.5% of the 24-week regimen compared to the 48-week regimen in patients with undetectable HCV RNA (target not detected) at weeks 4 and 12.The 540 enrolled patients had a median age of 51 years (range: 19 to 70); 60% of the patients were male; 32% had a body mass index ≥ 30 kg/m2; 14% were Black; 10% were Hispanic or Latino; 82% had baseline HCV RNA levels > 800,000 IU/ml; 16% had bridging fibrosis; 11% had cirrhosis; 72% had HCV genotype 1a; and 27% had HCV genotype 1b.A total of 352 (65%) patients had undetectable HCV RNA (target not detected) at weeks 4 and 12. Table 9 shows response rates. In patients who had undetectable HCV RNA (target not detected) at weeks 4 and 12, there was no additional benefit to extending peginterferon alfa-2a and ribavirin treatment to 48 weeks (difference in SVR rates of 2%; 95% confidence interval: -4%, 8%).
|Table 9: Response rates: Study 111|
|Patients with undetectable HCV RNA (target not detected) at weeks 4 and 12||T12/PRAll PatientsaN=540|
|Treatment outcome||T12/PR24N = 162||T12/PR48N = 160|
|SVR||92% (149/162) (87%, 96%)b||90% (144/160) (84%, 94%)b||74% (398/540) (70%, 77%)b|
|HCV RNA < 25 IU/ml at End of Treatment||98% (159/162)||93% (149/160)||79% (424/540)|
|Relapse||6% (10/159)||1% (2/149)||4% (19/424)|
|Table 10: SVR rates by extent of liver fibrosis at baseline: Study 111|
|Subgroup||Patients with undetectable HCV RNA (target not detected) at weeks 4 and 12||T12/PRAll Patientsa|
|No fibrosis, minimal fibrosis, or portal fibrosis||96% (119/124)||91% (115/127)||77% (302/391)|
|Bridging fibrosis||95% (19/20)||86% (18/21)||74% (65/88)|
|Cirrhosis||61% (11/18)||92% (11/12)||51% (31/61)|
Efficacy in previously treated adults
Study C216 (REALIZE)Study C216 was a randomised, double-blind, placebo-controlled, Phase 3 study conducted in patients who did not achieve SVR with prior treatment with peginterferon alfa-2a and ribavirin or peginterferon alfa-2b and ribavirin. The study enrolled prior relapsers (patients with HCV RNA undetectable at end of treatment with a pegylated interferon-based regimen, but HCV RNA detectable within 24 weeks of treatment follow-up) and prior non-responders (patients who did not have undetectable HCV RNA levels during or at the end of a prior course of at least 12 weeks of treatment). The non-responder-population was comprised of 2 subgroups: prior partial responders (greater than or equal to 2 log10 reduction in HCV RNA at week 12, but not achieving HCV RNA undetectable at end of treatment with a peginterferon and ribavirin) and prior null responders (less than 2 log10 reduction in HCV RNA at week 12 of prior treatment with peginterferon and ribavirin).Patients were randomised in a 2:2:1 ratio to one of three treatment groups: simultaneous start (T12/PR48): INCIVO from day 1 through week 12; delayed start (T12(DS)/PR48): INCIVO from week 5 through week 16; Pbo/PR48: placebo through week 16. All treatment regimens had a 48-week duration of peginterferon alfa-2a and ribavirin treatment.The 662 enrolled patients had a median age of 51 years (range: 21 to 70); 70% of the patients were male; 26% had a body mass index ≥ 30 kg/m2; 5% were Black; 11% were Hispanic or Latino; 89% had baseline HCV RNA levels > 800,000 IU/ml; 22% had bridging fibrosis; 26% had cirrhosis; 54% had HCV genotype 1a; and 46% had HCV genotype 1b.SVR rates for the T12(DS)/PR group were 88% (124/141) for prior relapsers, 56% (27/48) for prior partial responders, and 33% (25/75) for prior null responders. Table 11 shows the response rates for the recommended simultaneous start (T12/PR48) and the Pbo/PR48 arms.
|Table 11: Response rates: Study C216|
|Treatment outcome||T12/PR48% (n/N)||Pbo/PR48% (n/N)|
|Prior relapsersa||84% (122/145) (77%, 90%)b||22% (15/68) (13%, 34%)b|
|Prior partial respondersa||61% (30/49) (46%, 75%)b||15% (4/27) (4%, 34%)b|
|Prior null respondersa||31% (22/72) (20%, 43%)b||5% (2/37) (1%, 18%)b|
|HCV RNA < 25 IU/ml at End of Treatment|
|Prior relapsers||87% (126/145)||63% (43/68)|
|Prior partial responders||73% (36/49)||15% (4/27)|
|Prior null responders||39% (28/72)||11% (4/37)|
|Prior relapsers||3% (4/126)||63% (27/43)|
|Prior partial responders||17% (6/36)||0% (0/4)|
|Prior null responders||21% (6/28)||50% (2/4)|
|Table 12: SVR rates by extent of liver fibrosis at baseline: Study C216|
|Extent of liver fibrosis||T12/PR||Pbo/PR48|
|No or minimal fibrosis or portal fibrosis||84% (68/81)||32% (12/38)|
|Bridging fibrosis||86% (31/36)||13% (2/15)|
|Cirrhosis||82% (23/28)||7% (1/15)|
|Prior partial responders|
|No or minimal fibrosis or portal fibrosis||79% (19/24)||18% (3/17)|
|Bridging fibrosis||71% (5/7)||0 (0/5)|
|Cirrhosis||33% (6/18)||20% (1/5)|
|Prior null responders|
|No or minimal fibrosis or portal fibrosis||31% (9/29)||6% (1/18)|
|Bridging fibrosis||47% (8/17)||0 (0/9)|
|Cirrhosis||19% (5/26)||10% (1/10)|
|Table 13: SVR rates by week 4 response (< 1 log10 or ≥ 1 log10 reduction) in the T12(DS)/PR48 group: Study C216|
|Prior Treatment Response||T12(DS)/PR% (n/N)a|
|< 1 log10 reduction in HCV RNA at week 4||≥ 1 log10 reduction in HCV RNA at week 4|
|Prior partial responders||56% (10/18)||63% (17/27)|
|Prior null responders||15% (6/41)||54% (15/28)|
Study 106 and Study 107Study 106 was a randomised, double-blind, placebo-controlled, Phase 2 study that enrolled patients who had failed prior treatment with peginterferon alfa-2a and ribavirin or peginterferon alfa-2b and ribavirin. Among prior relapsers in the T12/PR24 treatment group who had undetectable HCV RNA (target not detected) at weeks 4 and 12 of treatment, the SVR rate was 89% (25/28) and the relapse rate was 7%.Study 107 was an open label, rollover study for patients who were treated in the control group (placebo, peginterferon alfa-2a, and ribavirin) of a Phase 2 study of telaprevir and who did not achieve SVR in the Phase 2 study. Among prior relapsers in the T12/PR24 treatment group who had undetectable HCV RNA (target not detected) at week 4 and 12 of treatment, the SVR rate was 100% (24/24).
Use of peginterferon alfa 2a or 2bTwo types of peginterferon alfa (2a and 2b) were studied in the Phase 2a open label, randomised study C208 in treatment-naïve patients.All patients received 12 weeks of INCIVO in combination with the peginterferon alfa/ribavirin standard therapy. Patients were randomised to 1 of 4 treatment groups:- INCIVO 750 mg every 8 hours with peginterferon alfa-2a 180 μg/week and ribavirin 1,000 or 1,200 mg/day- INCIVO 750 mg every 8 hours with peginterferon alfa-2b 1.5 μg/kg/week and ribavirin 800 or 1,200 mg/day- INCIVO 1,125 mg every 12 hours with peginterferon alfa-2a 180 μg/week and ribavirin 1,000 or 1,200 mg/day- INCIVO 1,125 mg every 12 hours with peginterferon alfa-2b 1.5 μg/kg/week and ribavirin 800 or 1,200 mg/day- Peginterferon alfa-2a/peginterferon alfa-2b and ribavirin were used according to their relevant Summary of Product Characteristics. At week 12, INCIVO dosing ended and patients continued on standard therapy only. 73.8% (59/80) of patients in the pooled peginterferon alfa-2a group met the criteria (undetectable HCV RNA (target not detected) at week 4 through week 20) for the shortened 24 week peginterferon/ribavirin treatment duration versus 61.7% (50/81) of patients in the pooled peginterferon alfa-2b group.
|Table 14: Pooled response rates: Study C208|
|Treatment outcome||T12P(2a)R48N = 80(%) n/N||T12P(2b)R48N = 81(%) n/N|
|SVRa||83.8 (67/80)||81.5 (66/81)|
|Viral breakthrough||5 (4/80)||12.3 (10/81)|
|Relapse||8.1 (6/74b)||4.2 (3/71b)|
Long-term efficacy data
Study 112 (EXTEND)A 3-year follow-up study of patients who achieved SVR with an INCIVO-based regimen showed that > 99% (122/123) of patients maintained their SVR status through the available follow-up period (median duration of 22 months).
Efficacy in adults with HCV/HIV-1 co-infection
Study 110Study 110 was a phase II randomised, double-blind, placebo-controlled study conducted in patients with chronic genotype 1 HCV/HIV co-infection who were treatment-naïve for hepatitis C. Patients were either not on antiretroviral therapy (CD4 count ≥ 500 cells/mm3), or had stable controlled HIV (HIV RNA < 50 copies/ml, CD4 count ≥ 300 cells/mm3) being treated with efavirenz or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine or lamivudine. Patients were randomised to 12 weeks of INCIVO (750 mg every 8 hours if taken in combination with atazanavir/ritonavir, tenofovir disoproxil fumarate, and emtricitabine or lamivudine OR 1,125 mg every 8 hours if taken in combination with efavirenz, tenofovir disoproxil fumarate, and emtricitabine) or placebo. All patients received peginterferon alfa-2a and ribavirin for 48 weeks. Fifty-five out of 60 patients received ribavirin at a fixed dose of 800 mg/day and the remaining 5 patients received a weight-based ribavirin dose. At baseline, 3 (8%) patients had bridging fibrosis and 2 (5%) patients had cirrhosis in the T12/PR48 arm. In the Pbo/PR arm, 2 (9%) patients had baseline bridging fibrosis and no patients had baseline cirrhosis. Table 15 shows the response rates for the T12/PR48 and the Pbo/PR48 arms. The response rate in the Pbo/PR arm was higher than that seen in other clinical studies of peginterferon bitherapy (historical SVR rates < 36%).
|Table 15: Response Rates: Study 110|
|Treatment Outcome||T12/PR48% (n/N)||Pbo/PR% (n/N)|
|Overall SVR12 ratea||74% (28/38)||45% (10/22)|
|Patients on an efavirenz-based regimen||69% (11/16)||50% (4/8)|
|Patients on an atazanavir/ritonavir-based regimen||80% (12/15)||50% (4/8)|
|Patients not receiving antiretroviral therapy||71% (5/7)||33% (2/6)|
Study HPC3008Study HPC3008 was an open-label, Phase 3b study conducted in patients with chronic genotype 1 HCV/HIV-1 co-infection who were treatment-naïve for hepatitis C or who did not achieve SVR with prior treatment with peginterferon alfa (2a or 2b) and ribavirin (including prior relapsers, prior partial responders and prior null responders). Patients were required to have an HIV-1 RNA < 50 copies/ml and CD4 count > 300 cells/mm3 at screening. Patients received INCIVO at a dosage of 750 mg every 8 hours, except for patients on an efavirenz-based regimen who received INCIVO at a dosage of 1125 mg every 8 hours. Treatment-naive patients or prior relapsers who were non-cirrhotic and achieved extended rapid virologic response (eRVR) received 12 weeks of treatment with INCIVO plus peginterferon alfa-2a and ribavirin followed by 12 weeks of treatment with peginterferon alfa-2a and ribavirin (total treatment duration of 24 weeks). Treatment-naive patients and prior relapsers who did not achieve eRVR, prior partial responders, prior null responders, and all cirrhotic patients received 12 weeks of treatment with INCIVO plus peginterferon alfa-2a and ribavirin followed by 36 weeks of treatment with peginterferon alfa-2a and ribavirin (total treatment duration of 48 weeks). All patients received ribavirin at a fixed dose of 800 mg/day. Antiretroviral therapy regimens included efavirenz, atazanavir/ritonavir, raltegravir, etravirine, or darunavir/ritonavir in combination with tenofovir or abacavir and either lamivudine or emtricitabine.The primary objective of the study was to assess the antiviral efficacy of INCIVO, peginterferon alfa-2a, and ribavirin in HCV/HIV-1 co-infected patients as measured by SVR12.The 162 enrolled patients had a median age of 46 years (range: 20 to 67 years); 78.4% of the patients were male; 6.8% had a body mass index ≥ 30 kg/m2; 4.3% were Black; 1.9% were Asian; 87.0% had baseline HCV RNA levels ≥ 800,000 IU/ml; 17.3% had bridging fibrosis; 13.0% had cirrhosis; 65.6% had HCV genotype 1a; 33.8% had HCV genotype 1b; 39.5% (n = 64) were HCV treatment-naïve; 17.9% (n = 29) were prior relapsers; 11.1% (n = 18) were prior partial responders; 31.5% (n = 51) were prior null responders. Median (range) CD4 cell count at baseline was 651 (277 to 1551 cells/mm3).Table 16 shows the response rates in treatment-naïve patients and in treatment-experienced patients by subgroup (treatment-naïve, prior relapsers and prior non-responders).
|Table 16: Treatment outcome in adult patients with genotype 1 HCV infection and HIV-1 co-infection in Study HPC3008)|
|Treatment-Experienced Patients by Subgroup|
|Treatment Outcome||Treatment-Naïve PatientsN = 64% (n/N)||Prior RelapsersN = 29% (n/N)||Prior Non-respondersaN = 69% (n/N)|
|SVR12||64.1% (41/64)||62.1% (18/29)||49.3% (34/69)|
|Undetectable HCV RNA (target not detected) at weeks 4 and 12||57.8% (37/64)||48.3% (14/29)||42.0% (29/69)|
|SVR in patients with undetectable HCV RNA (target not detected) at weeks 4 and 12||83.8% (31/37)||92.9% (13/14)||89.7% (26/29)|
|SVR in patients who did not have undetectable HCV RNA (target not detected) at weeks 4 and 12||37.0% (10/27)||33.3% (5/15)||20.0% (8/40)|
|SVR rates for patients with or without cirrhosis|
|Patients without cirrhosis||65.5% (38/58)||61.5% (16/26)||52.6% (30/57)|
|Patients with cirrhosis||50.0% (3/6)||66.7% (2/3)||33.3% (4/12)|
|Outcome for patients without SVR12|
|On-treatment virologic failureb||21.9% (14/64)||3.4% (1/29)||37.7% (26/69)|
|Relapsec||8.9% (4/45)||5.3% (1/19)||8.1% (3/37)|
|Otherd||7.8% (5/64)||31.0% (9/29)||8.7% (6/69)|
Clinical Studies Examining QT IntervalIn two double-blind, randomised, placebo- and active-controlled studies conducted to evaluate the effect on the QT interval, telaprevir monotherapy at a dose of 750 mg every 8 hours was not associated with a clinically relevant effect on QTcF interval. In one of those studies, a telaprevir 1,875 mg every 8 hours regimen was evaluated and the placebo-adjusted maximum mean increase in QTcF was 8.0 msec (90% CI: 5.1-10.9). Plasma concentrations with the telaprevir 1,875 mg every 8 hours dose used in this trial were comparable to those observed in studies in HCV-infected patients who received telaprevir 750 mg every 8 hours in combination with peginterferon alfa-2a and ribavirin.
Paediatric populationNo clinical studies have been performed in paediatric patients.The European Medicines Agency has deferred the obligation to submit the results of studies with INCIVO in one or more subsets of the paediatric population in chronic hepatitis C (see section 4.2 for information on paediatric use).
AbsorptionTelaprevir is orally available, most likely absorbed in the small intestine, with no evidence for absorption in the colon. Maximum plasma concentrations after a single dose of telaprevir are generally achieved after 4 5 hours. In vitro studies performed with human Caco-2 cells indicated that telaprevir is a substrate of P-glycoprotein (P-gp).Telaprevir exposure was similar regardless of whether the total daily dose of 2,250 mg was administered as 750 mg every 8 hours (q8h) or 1,125 mg twice daily (b.i.d.). Based upon population pharmacokinetic modeling of telaprevir steady-state exposures, the Geometric Mean Least Square Ratios (90% CI) of 1,125 mg twice daily (b.i.d.) versus 750 mg every 8 hours (q8h) were 1.08 (1.02; 1.13) for AUC24,ss, 0.878 (0.827; 0.930) for Ctrough,ss, and 1.18 (1.12;1.24) for Cmax,ss.The exposure to telaprevir was increased by 20% when taken following a high-fat caloric meal (56 g fat, 928 kcal) compared to an intake following a standard normal caloric meal (21 g fat, 533 kcal). When compared to administration following a standard normal caloric meal, exposure (AUC) decreased by 73% when telaprevir was taken on an empty stomach, by 26% following a low-calorie high-protein meal (9 g fat, 260 kcal), and by 39% following a low-calorie low-fat meal (3.6 g fat, 249 kcal). Therefore, telaprevir should be taken with food.
DistributionTelaprevir is approximately 59% to 76% bound to plasma proteins. Telaprevir binds primarily to alpha 1-acid glycoprotein and albumin.After oral administration, the typical apparent volume of distribution (Vd) was estimated to be 252 l, with an inter-individual variability of 72.2%.
BiotransformationTelaprevir is extensively metabolised in the liver, involving hydrolysis, oxidation, and reduction. Multiple metabolites were detected in faeces, plasma, and urine. After repeated oral administration, R-diastereomer of telaprevir (30-fold less active), pyrazinoic acid, and a metabolite that underwent reduction at the α-ketoamide bond of telaprevir (not active) were found to be the predominant metabolites of telaprevir.CYP3A4 is partly responsible for the metabolism of telaprevir. Other enzymes are also involved in the metabolism such as aldo-ketoreductases and other proteolytic enzymes. Studies using recombinant human CYP supersomes showed that telaprevir was a CYP3A4 inhibitor, and a time- and concentration-dependent inhibition of CYP3A4 by telaprevir was observed in human liver microsomes. No relevant inhibition by telaprevir of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 isozymes was observed in vitro. No relevant induction by telaprevir of CYP1A2, CYP2B6, CYP2C, and CYP3A isozymes was observed in vitro. Based on the results of drug-drug clinical interaction studies (e.g., escitalopram, zolpidem, ethinylestradiol), induction of metabolic enzymes by telaprevir cannot be excluded.In vitro studies demonstrated that telaprevir is not an inhibitor of UGT1A9 or UGT2B7. In vitro studies with recombinant UGT1A3 suggested that telaprevir may inhibit this enzyme. The clinical relevance of this is uncertain as administration of telaprevir with a single dose of buprenorphine, a partial UGT1A3 substrate, to healthy adult subjects did not result in increases in buprenorphine exposures. No relevant inhibition by telaprevir of alcohol dehydrogenase was observed in vitro. However, sufficiently high concentrations were not tested for intestinal inhibition to be excluded.Suppression by telaprevir and VRT-127394 of CYP enzymes regulated via CAR, PXR and Ah nuclear receptors was observed in vitro in human hepatocytes. Clinical drug-drug interaction studies with substrates of CYP2B6, CYP2C8, CYP2D6, CYP2C19 and UGT1A1, UGT2B7 and UGT1A3 indicate no clinically relevant impact of the suppression observed in vitro. For other enzymes and transporters (e.g., CYP1A1, CYP1A2, BCRP, OATPs) regulated by the same nuclear receptors, the potential clinical impact is unknown.
TransportersIn vitro studies demonstrated that telaprevir is an inhibitor of OATP1B1 and OATP2B1.No relevant inhibition by telaprevir of the organic cation transporter (OCT) OCT2 was observed in vitro.Telaprevir is a weak in vitro inhibitor of the transporters multidrug and toxin extrusion (MATE) MATE1 and MATE2-K with an IC50 of 28.3 μM and 32.5 μM, respectively. The clinical implications of this finding are currently unknown.
EliminationFollowing administration of a single oral dose of 750 mg 14C-telaprevir in healthy subjects, 90% of total radioactivity was recovered in faeces, urine and expired air within 96 hours post-dose. The median recovery of the administered radioactive dose was approximately 82% in the faeces, 9% in exhaled air and 1% in urine. The contribution of unchanged 14C telaprevir and VRT-127394 towards total radioactivity recovered in faeces was 31.8% and 18.7%, respectively.After oral administration, the apparent total clearance (Cl/F) was estimated to be 32.4 l/h with an inter-individual variability of 27.2%. The mean elimination half-life after single-dose oral administration of telaprevir 750 mg typically ranged from about 4.0 to 4.7 hours. At steady-state, the effective half-life is about 9-11 hours.
Linearity/non-linearityThe exposure (AUC) to telaprevir increased slightly greater than proportionally to the dose after single-dose administration of 375 up to 1,875 mg with food, possibly due to saturation of metabolic pathways or efflux transporters.An increase in dose from 750 mg every 8 hours to 1,875 mg every 8 hours in a multiple-dose study resulted in a less than proportional increase (i.e., about 40%) in telaprevir exposure.
Paediatric populationData in the paediatric population are currently not available.
Renal impairmentThe pharmacokinetics of telaprevir were assessed after administration of a single dose of 750 mg to HCV-negative subjects with severe renal impairment (CrCl < 30 ml/min). The mean telaprevir Cmax and AUC were 10% and 21% greater, respectively, compared to healthy subjects (see section 4.2).
Hepatic impairmentTelaprevir is primarily metabolised in the liver. Steady-state exposure to telaprevir was 15% lower in subjects with mild hepatic impairment (Child-Pugh Class A, score 5-6) compared to healthy subjects. Steady-state exposure to telaprevir was 46% lower in subjects with moderate hepatic impairment (Child-Pugh Class B, score 7-9) compared to healthy subjects. Effect on unbound telaprevir concentrations is unknown (see sections 4.2 and 4.4).
GenderThe effect of subject gender on telaprevir pharmacokinetics was evaluated using population pharmacokinetics of data from Phase 2 and 3 studies of INCIVO. No relevant effect of gender was identified.
RacePopulation pharmacokinetic analysis of INCIVO in HCV-infected subjects indicated that the exposure to telaprevir was similar in Blacks/African-Americans and Caucasians.
ElderlyThere is limited pharmacokinetic data on the use of INCIVO in HCV patients aged ≥ 65 years and no data in subjects > 70 years of age.
Animal toxicology and/or pharmacologyIn rats and dogs, telaprevir was associated with a reversible reduction of red blood cell parameters accompanied by a regenerative response. In both rats and dogs, AST/ALT elevations were observed in most studies, of which the increase in ALT in rats was not normalised after recovery. Histopathological findings in the liver were similar in both rat and dog studies, of which not all were fully resolved after recovery. In rats (but not in dogs), telaprevir caused degenerative changes in testes which were reversible and did not affect fertility. In general, exposure levels in relation to human values were low in animal pharmacology and toxicology studies.
Carcinogenesis and mutagenesisTelaprevir has not been tested for its carcinogenic potential. Neither telaprevir nor its major metabolite caused damage to DNA when tested in the standard battery of mutagenesis assays, in the presence and absence of metabolic activation.
Impairment of fertilityTelaprevir had no effects on fertility or fecundity when evaluated in rats.
Embryo-ftal developmentTelaprevir readily crosses the placenta in both rat and mouse giving a foetal: maternal exposure of 19 - 50%. Telaprevir did not have any teratogenic potential in rat or mouse. In a fertility and early embryonic development study in rats, an increase in non-viable conceptuses was observed. Dosing of the animals did not result in any exposure-margin when compared to human exposure.
Excretion into milkWhen administered to lactating rats, levels of telaprevir and its major metabolite were higher in milk compared to those observed in plasma. Rat offspring exposed to telaprevir in utero showed normal body weight at birth. However, when fed via milk from telaprevir-treated dams, body weight gain of rat pups was lower than normal (likely due to taste aversion). After weaning, rat pup body weight gain returned to normal.
Tablet corehypromellose acetate succinatecalcium hydrogen phosphate (anhydrous)microcrystalline cellulosesilica colloidal anhydroussodium lauryl sulfatecroscarmellose sodiumsodium stearyl fumarate
Tablet film-coatpolyvinyl alcoholmacrogoltalctitanium dioxide (E171)iron oxide yellow (E172)
50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
+44 (0)1494 567 568
+44 (0) 1494 567 445
+44 (0)1494 567 567
+44 (0)800 731 8450
+44 (0)800 731 5550